Lumos Pharma Inc reports results for the quarter ended in March - Earnings Summary

Lumos Pharma

03/05/2023 23:32

* Lumos Pharma Inc  LUMO.OQ  reported a quarterly adjusted
loss
of 89 cents​​ per share for the quarter ended in March. The mean
expectation of six analysts for the quarter was for a loss of
$1.12 per share.
    * Revenue rose 522.5% to $691.00 thousand from a year ago;
analysts expected $185.33 thousand. 
    * Lumos Pharma Inc's reported EPS for the quarter was a loss
of 89
cents​.
    * The mean earnings estimate of analysts had fallen by
about 16.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Lumos Pharma Inc shares had fallen by 3.3% this
quarter and
lost 11.4% so far this year.
    * The company reported a quarterly loss of $7.35 million.
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 10:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.12          -0.89          Beat
 Dec. 31 2022      -0.93          -0.99          Missed
 Sep. 30 2022      -1.01          -0.86          Beat
 Jun. 30 2022      -0.99          -0.94          Beat